WATCH: @elmayermd.bsky.social, of @danafarber.bsky.social and @harvardmed.bsky.social, highlights the @fda.gov approval of camizestrant plus a CDK4/6 inhibitor for HR+, HER2–, emergent ESR1-mutated breast cancer. #bcsm #oncology
Read our coverage of the approval: www.onclive.com/view/fda-app...
WATCH: @elmayermd.bsky.social, of @danafarber.bsky.social and @harvardmed.bsky.social, highlights the @fda.gov approval of camizestrant plus a CDK4/6 inhibitor for HR+, HER2–, emergent ESR1-mutated breast cancer. #bcsm #oncology Read our coverage of the approval: www.onclive.com/view/fda-app...
0 vue
Publié le 23/09/2026 20:25
WATCH: @elmayermd.bsky.social, of @danafarber.bsky.social and @harvardmed.bsky.social, highlights the @fda.gov approval of camizestrant plus a CDK4/6 inhibitor for HR+, HER2–, emergent ESR1-mutated breast cancer. #bcsm #oncology
Read our coverage of the approval: www.onclive.com/view/fda-app...
0 commentaire
?